RAPT Therapeutics (RAPT) Accumulated Depreciation & Amortization (2020 - 2024)
Historic Accumulated Depreciation & Amortization for Therapeutics (RAPT) over the last 5 years, with Q3 2024 value amounting to $9.8 million.
- Therapeutics' Accumulated Depreciation & Amortization rose 804.1% to $9.8 million in Q3 2024 from the same period last year, while for Sep 2024 it was $9.8 million, marking a year-over-year increase of 804.1%. This contributed to the annual value of $9.4 million for FY2023, which is 1355.32% up from last year.
- Per Therapeutics' latest filing, its Accumulated Depreciation & Amortization stood at $9.8 million for Q3 2024, which was up 804.1% from $9.6 million recorded in Q2 2024.
- In the past 5 years, Therapeutics' Accumulated Depreciation & Amortization registered a high of $9.8 million during Q3 2024, and its lowest value of $6.3 million during Q1 2020.
- Over the past 5 years, Therapeutics' median Accumulated Depreciation & Amortization value was $7.9 million (recorded in 2022), while the average stood at $8.1 million.
- Per our database at Business Quant, Therapeutics' Accumulated Depreciation & Amortization surged by 1764.14% in 2021 and then soared by 218.22% in 2022.
- Over the past 5 years, Therapeutics' Accumulated Depreciation & Amortization (Quarter) stood at $7.1 million in 2020, then increased by 8.5% to $7.7 million in 2021, then increased by 7.35% to $8.2 million in 2022, then rose by 13.55% to $9.4 million in 2023, then rose by 4.57% to $9.8 million in 2024.
- Its Accumulated Depreciation & Amortization stands at $9.8 million for Q3 2024, versus $9.6 million for Q2 2024 and $9.7 million for Q1 2024.